News
Pfizer boosts cancer drug roster with $14 billion Medivation deal
August 22, 2016 by admin · Leave a Comment
Medivation shares were up 20 percent at $80.43 in afternoon trading, just shy of the offer price of $81.50 per share. Shares of Pfizer, the largest U.S. drugmaker, were down 0.5 percent at $34.82. The offer is a 55-percent premium to Sanofi SA's initial offer to buy Medivation for $52.50 in April that pushed the San Francisco-based company to put itself up for sale.
Original post:
Pfizer boosts cancer drug roster with $14 billion Medivation deal